Long-Term Outcomes of Pegcetacoplan for GA Show Promise
Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth.
Source: medscape.com